News

conference

Oct 18, 2025

2025 - ESMO

Tumor-Selective MMAE Activation via CEACAM5 Pre-Targeting Using Click Chemistry: A First-in-Class Strategy to Enhance Clinical Benefit

Press

Oct 1, 2025

press release

Shasqi Strengthens Board of Directors With the Appointment of Former Chief Development Officer at Pfizer Oncology

publication

Jun 16, 2025

Clinical Cancer Research

Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial

press

Jun 16, 2025

press release

Shasqi Publishes Landmark Study in Clinical Cancer Research: First-in-Human Use of Click Chemistry Unlocks New Opportunities for Targeted Cancer Therapies

conference

Apr 27, 2025

2025 - AACR

Shasqi presented 2 posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting

conference

Apr 27, 2025

2025 - AACR

First-in-class Click Chemistry-Based Pre-Targeting of CEACAM5 Tumor Antigen Selectively Activates an MMAE Payload at Tumors

conference

Mar 5, 2025

2025 - World ADC London

CEACAM5 is an Ideal Target for Click Chemistry Enabled Pre-Targeting

media

Jan 23, 2025

Drug Discovery Trends

At JPM, Shasqi highlights how click chemistry can tackles ADC’s ‘1% problem’

press

Jan 8, 2025

press release

Shasqi to present at 43rd Annual J.P. Morgan healthcare Conference

conference

Nov 9, 2024

2024 SITC

Attenuated MMAE therapeutic activated by click chemistry at the tumor evokes potent immune responses

conference

Nov 9, 2024

2024 - SITC

Doxorubicin-based click chemistry therapeutic activates potent cytotoxic immune responses in advanced sarcoma patients in a Phase 1/2a clinical trial

conference

Nov 4, 2024

2024 World ADC

CEACAM5 is an Ideal Target for Click Chemistry Enabled Pre-Targeting